NASDAQ:SNTI - Nasdaq - US81726A2096 - Common Stock - Currency: USD
2.13
-0.19 (-8.19%)
The current stock price of SNTI is 2.13 USD. In the past month the price decreased by -24.2%. In the past year, price decreased by -33.44%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.74 | 339.94B | ||
AMGN | AMGEN INC | 14.22 | 158.77B | ||
GILD | GILEAD SCIENCES INC | 14.17 | 136.38B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 120.40B | ||
REGN | REGENERON PHARMACEUTICALS | 12.81 | 61.30B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.07B | ||
ARGX | ARGENX SE - ADR | 97.43 | 34.21B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.14B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.4 | 27.09B | ||
NTRA | NATERA INC | N/A | 21.91B | ||
BIIB | BIOGEN INC | 8.48 | 19.67B | ||
INSM | INSMED INC | N/A | 18.63B |
Senti Biosciences, Inc. is a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 34 full-time employees. The company went IPO on 2021-05-26. The firm is leveraging its synthetic biology platform to engineer gene circuits into new medicines with enhanced precision and control. These gene circuits are designed to kill cancer cells, to spare healthy cells, to increase specificity to target tissues, and/or to be controllable even after administration. Its product candidates include SENTI-202 and SENTI-301A. SENTI-202 is a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy. SENTI-301A is a multi-armed off-the-shelf healthy donor-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy product candidate designed for the treatment of GPC3 positive tumors.
SENTI BIOSCIENCES INC
2 Corporate Drive, First Floor
South San Francisco CALIFORNIA US
Employees: 48
Phone: 16502392030
The current stock price of SNTI is 2.13 USD. The price decreased by -8.19% in the last trading session.
The exchange symbol of SENTI BIOSCIENCES INC is SNTI and it is listed on the Nasdaq exchange.
SNTI stock is listed on the Nasdaq exchange.
8 analysts have analysed SNTI and the average price target is 12.24 USD. This implies a price increase of 474.65% is expected in the next year compared to the current price of 2.13. Check the SENTI BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SENTI BIOSCIENCES INC (SNTI) has a market capitalization of 55.55M USD. This makes SNTI a Micro Cap stock.
SENTI BIOSCIENCES INC (SNTI) currently has 48 employees.
SENTI BIOSCIENCES INC (SNTI) has a support level at 2.12 and a resistance level at 2.36. Check the full technical report for a detailed analysis of SNTI support and resistance levels.
The Revenue of SENTI BIOSCIENCES INC (SNTI) is expected to decline by -28.57% in the next year. Check the estimates tab for more information on the SNTI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SNTI does not pay a dividend.
SENTI BIOSCIENCES INC (SNTI) will report earnings on 2025-08-13.
SENTI BIOSCIENCES INC (SNTI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.54).
The outstanding short interest for SENTI BIOSCIENCES INC (SNTI) is 3.56% of its float. Check the ownership tab for more information on the SNTI short interest.
ChartMill assigns a fundamental rating of 3 / 10 to SNTI. The financial health of SNTI is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months SNTI reported a non-GAAP Earnings per Share(EPS) of -11.54. The EPS decreased by -115.47% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -53.95% | ||
ROE | -104.01% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to SNTI. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 83.91% and a revenue growth -28.57% for SNTI